Stock fact sheet · data as of

908 Devices Inc. (MASS): fair value, margin of safety and Wheel Score

Healthcare · Medical - Specialties · United States · Speculative / Distressed

Close11.89
GLS fair value0.29931 of 9 models
Margin of safety-3872%price above fair value
Wheel Score32Weakout of 100
Health3/9Piotroski F-score
Moat2.0/10GLS 10-year score
Market cap$491M275k shares a day
Implied vol.88%near-the-money, 20-60 d
P/E-EPS -0.91
Dividend yieldnone
Beta0.63moves less than the market
Next earnings9 Nov 2026in 24 days (before the open)

Is MASS undervalued?

MASS closed at 11.89 on 16 Oct 2026, more than 30% above the GLS average fair value of 0.2993. Only 0 of the 1 models that produced a value sit above the price. By our models the shares are priced well beyond what the filed earnings, cash flow and book value support; the Sunday Scan drops names like this at the "below fair value" rule.

Only 1 of the nine models produced a value (10 Cap); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.

The nightly engine files MASS under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for MASS

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap0.2993-97%Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)2.38-80%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target12.00+1%Analysts' average 12-month price target. Not in the average

Quality and financial health

Financial health is weak: MASS passes 3 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 2.0 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are thin or negative - ROIC -22.8%, ROE -25.5%, ROA -19.3% - with debt at 0.12 times equity and a free-cash-flow yield of 0.1%.

908 Devices Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Device Sales 69%, Recurring 31%, Contract 1% (quarter Q2 FY2026).

Institutional ownership scores 9/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score3 / 9ROIC-22.8%
GLS Moat2.0 / 10ROE-25.5%
Debt / equity0.12ROA-19.3%
Free-cash-flow yield0.1%Payout ratio0%
Institutions9 / 10Insiders · Congress1 · 5 / 10

Wheel Score 32: Weak

MASS scores 32 out of 100 on the Wheel Score, in the Weak band (under 50). Value 0/25, Health 7/20, Moat 3/15, Premium 13/20, Stability 9/20. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.

Implied volatility is 88% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (13 of 20) because volatility this high usually comes with a reason. Chain open interest is thin - 1,771 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.

Volume runs at 275k shares a day on a market cap of $491M, with a beta of 0.63 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 9 of 20.

PartPointsFrom
Value0 / 25-3872% margin of safety
Health7 / 20Piotroski 3/9
Moat3 / 15moat 2.0/10
Premium13 / 20implied volatility 88%
Stability9 / 20275k shares/day, $491M cap, beta 0.63

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 9 Nov 2026 (before the open), 24 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Specialties

The 12 companies below are the closest to 908 Devices Inc. by market cap within the Medical - Specialties industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
BWAY
BrainsWay Ltd.
11.828.13-45%33Weak$464M
SI
Shoulder Innovations, Inc.
17.87--26No options$372M
MLAB
Mesa Laboratories, Inc.
127.7445.24-182%28No options$715M
ANIK
Anika Therapeutics, Inc.
20.692.47-737%40Weak$277M
MOBI
Mobia Medical, Inc. Common Stock
8.31--22No options$277M
LAB
Standard BioTools Inc.
0.6584--36Weak$258M
QDEL
QuidelOrtho Corporation
13.87--45Weak$951M
TRIB
Trinity Biotech plc
6.61--26Weak$134M
NYXH
Nyxoah S.A.
1.19--26No options$121M
APYX
Apyx Medical Corporation
2.56--35Weak$108M
SKIN
SkinHealth Systems Inc.
11.5667.34+83%45Weak$75M
DRIO
DarioHealth Corp.
5.13119.64+96%39No options$50M

⚖ Compare MASS with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about MASS

Is MASS undervalued right now?

No: at 11.89 the stock trades 3872% above the GLS average fair value of 0.2993 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.

What is the Wheel Score of MASS and what does it mean?

MASS scores 32 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for MASS?

0.2993 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does 908 Devices Inc. report earnings next?

The next earnings report is due on 9 Nov 2026 (before the open), 24 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does MASS have listed options, and how liquid are they?

Yes. The nightly snapshot found 90 listed contracts with 1,771 open interest across all expiries and implied volatility of 88% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.